BrightGene Bio-Medical Technology Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 304.94 million compared to CNY 248.37 million a year ago. Revenue was CNY 304.94 million compared to CNY 248.37 million a year ago.

Net income was CNY 70.77 million compared to CNY 60.75 million a year ago. Basic earnings per share from continuing operations was CNY 0.17 compared to CNY 0.15 a year ago. Diluted earnings per share from continuing operations was CNY 0.17 compared to CNY 0.15 a year ago.